Optimization of Peptide Inhibitors of β-Klotho as Antagonists of Fibroblast Growth Factors 19 and 21

[Image: see text] Fibroblast growth factors 19 and 21 (FGF19 and FGF21) have biological actions that render them promising clinical candidates for treatment of metabolic diseases, particularly dyslipidemia and nonalcoholic steatohepatitis (NASH). These two atypical endocrine FGFs employ an accessory...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:ACS Pharmacol Transl Sci
Auteurs principaux: Pan, Jia, Parlee, Sebastian D., Brunel, Florence M., Li, Pengyun, Lu, Wei, Perez-Tilve, Diego, Liu, Fa, Finan, Brian, Kharitonenkov, Alexei, DiMarchi, Richard D.
Format: Artigo
Langue:Inglês
Publié: American Chemical Society 2020
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7551714/
https://ncbi.nlm.nih.gov/pubmed/33073195
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsptsci.0c00100
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires